IQVIA (IQV) Stock Forecast & Price Target

$236.97

+2.18 (+0.93%)

(As of 09/30/2024 ET)

IQVIA - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 17 Analyst Ratings

Sell
0

Hold
4

Buy
13

Based on 17 Wall Street analysts who have issued ratings for IQVIA in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 17 analysts, 4 have given a hold rating, 12 have given a buy rating, and 1 has given a strong buy rating for IQV.

Consensus Price Target

$267.00
12.67% Upside

According to the 17 analysts' twelve-month price targets for IQVIA, the average price target is $267.00. The highest price target for IQV is $300.00, while the lowest price target for IQV is $220.00. The average price target represents a forecasted upside of 12.67% from the current price of $236.97.

Get the Latest News and Ratings for IQV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for IQVIA and its competitors.

IQV Analyst Ratings Over Time

Type	Current Forecast 10/2/23 to 10/1/24	1 Month Ago 9/2/23 to 9/1/24	3 Months Ago 7/4/23 to 7/3/24	1 Year Ago 10/2/22 to 10/2/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	12 Buy rating(s)	12 Buy rating(s)	13 Buy rating(s)	13 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	3 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$267.00	$265.67	$257.73	$251.64
Forecasted Upside	12.67% Upside	5.61% Upside	24.72% Upside	29.75% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Retire off just one stock ticker? (Ad)

ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT make you rich. However, there is one stock that stands head and shoulders above everything else. It's currently trading for only $15...

Click here for the ticker >>>

IQV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

IQV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

IQVIA Stock vs. The Competition

Type	IQVIA	Medical Companies	S&P 500
Consensus Rating Score	2.82	2.78	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	12.67% Upside	823.07% Upside	6.15% Upside
News Sentiment Rating	Positive News See Recent IQV News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/20/2024	Robert W. Baird 2 of 5 stars		Boost Target	Neutral ➝ Neutral	$251.00 ➝ $256.00	+4.65%
9/4/2024	Royal Bank of Canada 4 of 5 stars	S. Dodge Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$275.00	+10.57%
8/5/2024	JPMorgan Chase & Co. 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$260.00 ➝ $288.00	+23.01%
7/31/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Toung Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/24/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$266.00 ➝ $242.00	+1.34%
7/23/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$270.00 ➝ $280.00	+16.57%
Get the Latest News and Ratings for IQV and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for IQVIA and its competitors with MarketBeat's FREE daily newsletter.
7/23/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$295.00 ➝ $300.00	+24.28%
7/23/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$230.00 ➝ $270.00	+12.66%
7/23/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$292.00 ➝ $300.00	+25.18%
7/23/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$255.00 ➝ $275.00	+12.14%
6/6/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$270.00	+23.30%
2/26/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Davis Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
2/26/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$290.00	+17.29%
2/15/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral
2/13/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$285.00	+30.81%
12/11/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$190.00 ➝ $225.00	+4.52%
10/10/2023	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$250.00 ➝ $229.00	+14.76%
9/6/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$260.00	+17.71%
8/2/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$255.00 ➝ $281.00	+28.44%
5/1/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$235.00 ➝ $220.00	+16.88%
2/13/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform	$265.00	+14.17%
12/6/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$251.00	+18.44%
10/18/2022	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$290.00 ➝ $270.00	+49.02%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 07:26 AM ET.

Should I Buy IQVIA Stock? IQV Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, September 24, 2024. Please send any questions or comments about these IQVIA pros and cons to contact@marketbeat.com.

IQVIA
Bull Case

Here are some ways that investors could benefit from investing in IQVIA Holdings Inc.:

IQVIA has consistently received positive ratings from analysts, with a consensus rating of "Moderate Buy" and an average target price of $266.67, indicating potential for growth.
The company reported strong quarterly earnings results, beating analysts' estimates and demonstrating a solid financial performance.
Recent insider activity, such as the sale of shares by an insider at a price of $246.33, could indicate confidence in the company's future prospects.
IQVIA's stock price has shown resilience, trading at $238.40 with a market capitalization of $43.44 billion, reflecting investor interest and stability.
The company's focus on advanced analytics, technology solutions, and clinical research services positions it well in the life sciences industry, offering potential for innovation and market leadership.

IQVIA
Bear Case

Investors should be bearish about investing in IQVIA Holdings Inc. for these reasons:

Despite positive ratings, there have been downgrades by some analysts, indicating potential risks or uncertainties in the company's future performance.
The stock's price-to-earnings ratio of 32.42 and a PEG ratio of 2.29 may suggest that the stock is currently trading at a premium valuation, potentially limiting short-term gains.
IQVIA's debt-to-equity ratio of 1.80 may raise concerns about the company's leverage and financial stability, impacting investor confidence.
While the company has shown growth, the beta of 1.49 indicates higher volatility compared to the market average, which could lead to fluctuations in the stock price.
Investors should consider market conditions and industry competition, as these factors can influence IQVIA's performance and stock price in the future.

IQV Forecast - Frequently Asked Questions

: According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for IQVIA is $267.00, with a high forecast of $300.00 and a low forecast of $220.00.
: 17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IQVIA in the last twelve months. There are currently 4 hold ratings, 12 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IQV shares.
: According to analysts, IQVIA's stock has a predicted upside of 12.67% based on their 12-month stock forecasts.
: Over the previous 90 days, IQVIA's stock had 1 upgrade and 1 downgrade by analysts.
: IQVIA has been rated by research analysts at Argus, Barclays, Evercore ISI, Jefferies Financial Group, JPMorgan Chase & Co., Morgan Stanley, Robert W. Baird, Royal Bank of Canada, Truist Financial, and UBS Group in the past 90 days.
: Analysts like IQVIA more than other "medical" companies. The consensus rating score for IQVIA is 2.82 while the average consensus rating score for "medical" companies is 2.78. Learn more on how IQV compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

Does Elon Musk control the U.S. gov’t? (Ad)

Elon has been advising the government to reopen America’s nuclear facilities for years, and now, with the help of Biden’s ADVANCE act, these facilities are once again going back online just as he requested. One company is poised to benefit from America’s nuclear revival like no other. Elon Musk is one of the few people who knows this.

Watch this new documentary and you’ll discover what Elon knows,

This page (NYSE:IQV) was last updated on 10/1/2024 by MarketBeat.com Staff

From Our Partners